Insulet (PODD) Cash & Equivalents (2010 - 2026)

Insulet (PODD) has 17 years of Cash & Equivalents data on file, last reported at $480.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 62.56% year-over-year to $480.4 million; the trailing twelve-month figure through Mar 2026 stood at $480.4 million (down 62.56% YoY), and the FY2025 full-year result was $716.1 million, down 24.89% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $480.4 million, down from $716.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q1 2025 and bottomed at $480.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $716.1 million (2025), against an average of $780.7 million.
• The widest annual swing landed in 2025, when Cash & Equivalents surged 70.81%; it then tumbled 62.56% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $674.7 million in 2022, then gained by 4.37% to $704.2 million in 2023, then surged by 35.39% to $953.4 million in 2024, then dropped by 24.89% to $716.1 million in 2025, then slumped by 32.91% to $480.4 million in 2026.
• The last three Cash & Equivalents figures came in at $480.4 million (Q1 2026), $716.1 million (Q4 2025), and $757.4 million (Q3 2025), per Business Quant data.

Peer Comparison